Is Meloxicam Good for Lower Back Pain?

Meloxicam is an effective option for lower back pain, particularly for acute flare-ups. In a large observational study of patients with acute nonspecific back pain, a daily dose achieved complete pain relief in about three-quarters of participants within roughly nine days of treatment. That puts it on par with other commonly prescribed anti-inflammatory drugs like diclofenac and celecoxib, but meloxicam tends to be gentler on the stomach, which is a meaningful advantage when you need daily pain control for a week or more.

What Makes Meloxicam Work for Back Pain

Meloxicam belongs to the family of nonsteroidal anti-inflammatory drugs, but it sits in a particular niche within that family. It preferentially targets the COX-2 enzyme, the one your body ramps up during inflammation, while largely sparing COX-1, which handles routine housekeeping tasks like protecting your stomach lining and supporting kidney blood flow.¹ This selectivity matters in practice. Most lower back pain involves an inflammatory component, whether it comes from a muscle strain, a disc irritation, or degenerative changes in the spine. By tamping down that inflammation without hitting COX-1 as hard, meloxicam relieves pain while producing fewer gut-related side effects than older anti-inflammatories.

The practical appeal for back pain sufferers is convenience, too. Meloxicam is typically taken once a day, unlike ibuprofen or diclofenac, which require multiple doses throughout the day. When you are dealing with back pain that wakes you up at night or makes it hard to get through a workday, having one pill to manage for 24 hours simplifies things.

The Evidence for Acute Lower Back Pain

The strongest case for meloxicam in back pain comes from acute episodes, the kind of sudden flare-up that sends people searching for something stronger than over-the-counter options. A multicenter study of patients with acute nonspecific back pain found that meloxicam at 15 mg per day achieved complete pain relief in about 75% of participants, with the average treatment period lasting around eight to nine days. Adverse events were reported in fewer than 5% of patients.²

That study also identified some useful patterns. Patients under 65, those experiencing their first episode of back pain, and those who had previously responded well to anti-inflammatories tended to do better. On the flip side, people with severe baseline pain (a score of 7 or higher on a 10-point scale), pain that persisted at rest or at night, and especially those with sciatica had less favorable outcomes. That does not mean meloxicam failed those patients entirely; it means the drug worked better when inflammation was the primary driver rather than nerve compression or structural damage.

When Sciatica Is Involved

Sciatica, the radiating leg pain caused by irritation of the sciatic nerve, often accompanies lower back problems and can be harder to treat than localized back pain alone. Two randomized, double-blind trials tested meloxicam head-to-head against both placebo and diclofenac in patients with acute sciatica. Both doses of meloxicam (7.5 mg and 15 mg) significantly improved overall pain by day seven compared with placebo, and the improvement was comparable to what diclofenac 150 mg achieved.³ Meloxicam was also well tolerated across both trials.

This is worth knowing because sciatica is one of the conditions where patients most commonly wonder whether an anti-inflammatory will be “strong enough.” The evidence suggests that meloxicam handles sciatica about as well as diclofenac, which has long been considered one of the more potent over-the-counter-class anti-inflammatories. The difference is that meloxicam does it with a once-daily dose and a gentler side-effect profile.

Inflammatory Back Conditions Like Ankylosing Spondylitis

Lower back pain is not always caused by muscle strain or disc problems. Ankylosing spondylitis, a chronic inflammatory condition that primarily affects the spine, is another common culprit, especially in younger adults. A network meta-analysis of randomized controlled trials found that all NSAIDs tested, including meloxicam, were highly effective and well-tolerated in reducing pain and improving function in ankylosing spondylitis.⁴ The pain reduction across the six NSAIDs analyzed was clinically meaningful and significantly better than placebo.

For people whose back pain stems from an inflammatory spinal condition rather than a mechanical injury, meloxicam can be a particularly good fit because these conditions often require daily anti-inflammatory treatment over longer stretches. The once-daily dosing and relatively favorable GI profile make sustained use more practical compared with drugs that demand three-times-daily dosing and carry higher stomach risks.

How Meloxicam Compares to Other Anti-Inflammatories

One of the most common questions people have is whether meloxicam is better or worse than the alternatives. The honest answer is that it is roughly equivalent in pain relief to most other NSAIDs for back pain, with some trade-offs on the safety side.

A study comparing celecoxib and meloxicam in patients with nonspecific lower back pain found that both drugs caused the same significant reduction in pain severity and the same degree of functional improvement. Both also produced rare adverse events at similar rates, including stomach irritation and blood pressure increases.⁵ So if you have tried celecoxib and it worked, meloxicam is likely to work similarly, and vice versa.

A systematic review and economic evaluation that looked at COX-2 selective NSAIDs across osteoarthritis and rheumatoid arthritis found that these drugs were generally as effective as traditional NSAIDs while producing fewer serious upper gastrointestinal events. Meloxicam specifically was rated as equivalent or slightly inferior in efficacy compared with other COX-2 selective options in some analyses, though the clinical difference was small enough that it often came down to tolerability and cost.⁶

In surgical pain settings, meloxicam and celecoxib performed similarly for pain control after knee replacement surgery, with comparable rates of GI bleeding across both drugs.⁷ Wound complication rates did not significantly differ between the groups either. These surgical findings are relevant because post-surgical pain is a reasonable proxy for how well a drug handles the kind of intense, inflammatory pain that a severe back episode can produce.

The Stomach Advantage

One area where meloxicam genuinely stands out among NSAIDs is gastrointestinal tolerability. A comparison between meloxicam and diclofenac in osteoarthritis patients found that meloxicam was easier on the stomach, with lower rates of abdominal pain as a side effect over both two-week and four-week treatment periods.⁸ This matters for lower back pain because treatment courses often run one to two weeks, sometimes longer for stubborn episodes, and stomach irritation is the most common reason people abandon an NSAID before their pain has resolved.

The broader evidence from the systematic review mentioned earlier confirmed this pattern: COX-2 selective NSAIDs as a class were associated with significantly fewer clinical upper GI events than traditional, nonselective NSAIDs.⁶ If you have a history of stomach ulcers, heartburn, or you simply know from experience that anti-inflammatories upset your gut, meloxicam is a reasonable choice to discuss with your doctor.

Heart and Kidney Risks You Should Know About

No NSAID is risk-free, and meloxicam is no exception. The cardiovascular picture deserves attention. A population-based study found that current use of meloxicam was associated with roughly a 38% higher risk of heart attack compared with people who had used NSAIDs in the past but were not currently taking them. Current diclofenac use carried a similar increase, while naproxen showed a smaller and statistically uncertain bump.⁹ This does not mean that taking meloxicam for a week-long back episode will give you a heart attack, but it does mean that people with existing heart disease or significant cardiovascular risk factors should be cautious and keep treatment courses as short as possible.

The kidney story is also worth understanding. A case-control study found that current meloxicam users had roughly double the odds of chronic kidney disease compared with nonusers, and the risk climbed further with cumulative exposure. Among people who had used meloxicam for more than six months, the odds increased substantially.¹⁰ There have also been case reports of acute kidney injury occurring within just a few days of starting meloxicam, though such events are rare.¹¹

The practical takeaway is straightforward. For a short course treating an acute back pain episode, the kidney and heart risks are small for most people. The risks accumulate with long-term or repeated use, so if you find yourself reaching for meloxicam every month, it is time to explore other approaches with your doctor rather than staying on the drug indefinitely.

Combining Meloxicam with a Muscle Relaxant

Lower back pain often involves muscle spasm alongside inflammation, and many doctors prescribe a muscle relaxant on top of an anti-inflammatory. There is some evidence supporting this approach. A study comparing a single NSAID to the combination of an NSAID plus a muscle relaxant found that the combination was significantly more effective at reducing lower back pain severity.¹² That particular study used diclofenac rather than meloxicam as the NSAID, but the principle applies broadly: when both inflammation and spasm are contributing to your pain, addressing both pathways works better than addressing just one.

If your back pain came on suddenly after lifting something or an awkward movement, and the muscles around your lower spine feel rock-hard and locked up, asking your prescriber about adding a short course of a muscle relaxant to meloxicam is reasonable. The trade-off is that muscle relaxants cause drowsiness, so you may not want to drive or operate equipment while taking the combination.

Meloxicam for Older Adults and People with Other Health Conditions

Back pain is common across all age groups, but it becomes particularly prevalent as people get older, right when the risks of anti-inflammatory drugs also start climbing. Several studies have examined meloxicam in elderly patients and those with conditions like high blood pressure, diabetes, and gastrointestinal problems. The evidence from these studies supports the view that meloxicam can be recommended for older patients and those with certain comorbid conditions, given its favorable balance of effectiveness and safety compared with less selective NSAIDs.¹³

That said, “can be recommended” is not the same as “safe for everyone.” The acute back pain study found that patients over 65 had less favorable outcomes than younger patients.² Older adults are also more susceptible to the kidney and cardiovascular risks discussed earlier. The guidance for older patients is generally to use the lowest effective dose for the shortest duration, to stay well hydrated, and to monitor kidney function if treatment extends beyond a few days.

Newer Formulations on the Horizon

One limitation of standard meloxicam is its slow onset. Because of how the drug dissolves and absorbs, it can take several hours to reach peak levels in your blood, which is not ideal when you are in acute pain and want relief now. Researchers have been working on faster-acting versions.

A nanoparticle-based oral formulation of meloxicam has shown significantly faster absorption and higher intestinal penetration compared with traditional meloxicam preparations in preclinical work.¹⁴ The faster absorption also means a lower dose could potentially achieve the same pain-relieving effect, which in turn would reduce the risk of GI side effects.

On the commercial front, the FDA has accepted a new drug application for a fast-acting oral meloxicam formulation designed for moderate to severe acute pain. In clinical trials, this formulation achieved faster times to meaningful pain relief compared with placebo, and performed comparably to tramadol, a prescription pain reliever in a completely different drug class.¹⁵ If approved, this could expand meloxicam’s role in acute pain settings, including those sudden lower back episodes where people are currently reaching for opioid-class drugs because they need fast relief.

When Meloxicam Might Not Be the Right Choice

Not every type of lower back pain responds equally well to anti-inflammatory drugs. Meloxicam works by reducing inflammation, so it is best suited for pain that has an inflammatory component. Chronic, diffuse lower back pain that has persisted for months without a clear inflammatory trigger may respond poorly. Pain from conditions like spinal stenosis, where the problem is structural narrowing of the spinal canal, often needs different approaches. And neuropathic pain, the burning or electrical-shock type pain that comes from nerve damage, does not typically respond well to any NSAID.

People taking blood thinners, those with a history of stomach ulcers or bleeding, anyone with moderate to severe kidney disease, and people who have had a recent heart attack or stroke should generally avoid meloxicam or use it only under close medical supervision. The drug also interacts with certain blood pressure medications, lithium, and methotrexate, so if you take any of these, check with your pharmacist or prescriber before starting meloxicam.

Pregnant women, particularly in the third trimester, should not use meloxicam or any NSAID, as these drugs can cause problems with fetal heart development and reduce amniotic fluid. This is a class-wide restriction, not specific to meloxicam, but it catches some people off guard because anti-inflammatories feel like mild, everyday medications.